{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:01:58Z","timestamp":1790643718868,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171722"],"award-info":[{"award-number":["82171722"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471772"],"award-info":[{"award-number":["82471772"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271764"],"award-info":[{"award-number":["82271764"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L246015"],"award-info":[{"award-number":["L246015"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01256-9","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:56:35Z","timestamp":1783356995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 inhibition induces autophagic flux blockade and sensitizes pancreatic cancer to EGFR-targeted therapy"],"prefix":"10.1007","volume":"49","author":[{"given":"Yuxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enkui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weikang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinmo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-754X","authenticated-orcid":false,"given":"Yongsu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-5161","authenticated-orcid":false,"given":"Xiaodong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"1","key":"1256_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"R.L. Siegel, A.N. Giaquinto, A. Jemal, Cancer statistics, 2024. CA Cancer J. Clin. 74(1), 12\u201349 (2024). https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"1256_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/ags3.12273","volume":"3","author":"W Niesen","year":"2019","unstructured":"W. Niesen, T. Hank, M. B\u00fcchler, O. Strobel, Local radicality and survival outcome of pancreatic cancer surgery. Ann. Gastroenterol. Surg. 3(5), 464\u2013475 (2019). https:\/\/doi.org\/10.1002\/ags3.12273","journal-title":"Ann. Gastroenterol. Surg."},{"key":"1256_CR3","doi-asserted-by":"publisher","first-page":"115647","DOI":"10.1016\/j.addr.2025.115647","volume":"224","author":"T Toit-Thompson","year":"2025","unstructured":"T. Toit-Thompson, L. Leck, J. Gillson, N. Pavlakis, A.J. Gill, J.S. Samra, A. Mittal, S. Sahni, Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies. Adv. Drug Deliv Rev. 224, 115647 (2025). https:\/\/doi.org\/10.1016\/j.addr.2025.115647","journal-title":"Adv. Drug Deliv Rev."},{"issue":"1","key":"1256_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12943-020-01169-7","volume":"19","author":"C Qin","year":"2020","unstructured":"C. Qin, G. Yang, J. Yang, B. Ren, H. Wang, G. Chen, F. Zhao, L. You, W. Wang, Y. Zhao, Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol. Cancer. 19(1), 50 (2020). https:\/\/doi.org\/10.1186\/s12943-020-01169-7","journal-title":"Mol. Cancer"},{"key":"1256_CR5","doi-asserted-by":"publisher","unstructured":"L. Yan, P. Raj, W. Yao, H. Ying, Glucose Metabolism in Pancreatic Cancer. Cancers (Basel). 11(10) (2019). https:\/\/doi.org\/10.3390\/cancers11101460","DOI":"10.3390\/cancers11101460"},{"issue":"6","key":"1256_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.molmed.2024.03.008","volume":"30","author":"MC De Santis","year":"2024","unstructured":"M.C. De Santis, B. Bockorny, E. Hirsch, P. Cappello, M. Martini, Exploiting pancreatic cancer metabolism: challenges and opportunities. Trends Mol. Med. 30(6), 592\u2013604 (2024). https:\/\/doi.org\/10.1016\/j.molmed.2024.03.008","journal-title":"Trends Mol. Med."},{"issue":"11","key":"1256_CR7","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1080\/15548627.2020.1847462","volume":"17","author":"J Li","year":"2020","unstructured":"J. Li, X. Chen, R. Kang, H. Zeh, D.J. Klionsky, D. Tang, Regulation and function of autophagy in pancreatic cancer. Autophagy. 17(11), 3275\u20133296 (2020). https:\/\/doi.org\/10.1080\/15548627.2020.1847462","journal-title":"Autophagy"},{"key":"1256_CR8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.pharmthera.2016.10.017","volume":"170","author":"H Koepsell","year":"2016","unstructured":"H. Koepsell, The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol. Ther. 170, 148\u2013165 (2016). https:\/\/doi.org\/10.1016\/j.pharmthera.2016.10.017","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"1256_CR9","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00424-020-02433-x","volume":"472","author":"G Gyimesi","year":"2020","unstructured":"G. Gyimesi, J. Pujol-Gim\u00e9nez, Y. Kanai, M.A. Hediger, Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application. Pflugers Arch. 472(9), 1177\u20131206 (2020). https:\/\/doi.org\/10.1007\/s00424-020-02433-x","journal-title":"Pflugers Arch."},{"issue":"30","key":"1256_CR10","doi-asserted-by":"publisher","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","volume":"112","author":"C Scafoglio","year":"2015","unstructured":"C. Scafoglio, B.A. Hirayama, V. Kepe, J. Liu, C. Ghezzi, N. Satyamurthy, N.A. Moatamed, J. Huang, H. Koepsell, J.R. Barrio, E.M. Wright, Functional expression of sodium-glucose transporters in cancer. Proc. Natl. Acad. Sci. U S A 112(30), E4111\u2013E4119 (2015). https:\/\/doi.org\/10.1073\/pnas.1511698112","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"1256_CR11","doi-asserted-by":"publisher","unstructured":"C.R. Scafoglio, B. Villegas, G. Abdelhady, S.T. Bailey, J. Liu, A.S. Shirali, W.D. Wallace, C.E. Magyar, T.R. Grogan, D. Elashoff, T. Walser, J. Yanagawa, D.R. Aberle, J.R. Barrio, S.M. Dubinett, D.B. Shackelford, Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci. Transl Med. 10(467) (2018). https:\/\/doi.org\/10.1126\/scitranslmed.aat5933","DOI":"10.1126\/scitranslmed.aat5933"},{"issue":"4","key":"1256_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.neo.2021.02.003","volume":"23","author":"D Papadopoli","year":"2021","unstructured":"D. Papadopoli, O. Uchenunu, R. Palia, N. Chekkal, L. Hulea, I. Topisirovic, M. Pollak, J. St-Pierre, Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. Neoplasia. 23(4), 391\u2013399 (2021). https:\/\/doi.org\/10.1016\/j.neo.2021.02.003","journal-title":"Neoplasia"},{"key":"1256_CR13","doi-asserted-by":"publisher","unstructured":"L. Ding, X. Chen, W. Zhang, X. Dai, H. Guo, X. Pan, Y. Xu, J. Feng, M. Yuan, X. Gao, J. Wang, X. Xu, S. Li, H. Wu, J. Cao, Q. He, B. Yang, Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J. Clin. Invest. 133(1) (2023). https:\/\/doi.org\/10.1172\/JCI154754","DOI":"10.1172\/JCI154754"},{"issue":"6","key":"1256_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41419-022-04980-w","volume":"13","author":"W Wu","year":"2022","unstructured":"W. Wu, Z. Zhang, D. Jing, X. Huang, D. Ren, Z. Shao, Z. Zhang, SGLT2 inhibitor activates the STING\/IRF3\/IFN-\u03b2 pathway and induces immune infiltration in osteosarcoma. Cell. Death Dis. 13(6), 523 (2022). https:\/\/doi.org\/10.1038\/s41419-022-04980-w","journal-title":"Cell. Death Dis."},{"issue":"8","key":"1256_CR15","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/ijc.31193","volume":"142","author":"K Kaji","year":"2017","unstructured":"K. Kaji, N. Nishimura, K. Seki, S. Sato, S. Saikawa, K. Nakanishi, M. Furukawa, H. Kawaratani, M. Kitade, K. Moriya, T. Namisaki, H. Yoshiji, Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int. J. Cancer. 142(8), 1712\u20131722 (2017). https:\/\/doi.org\/10.1002\/ijc.31193","journal-title":"Int. J. Cancer"},{"issue":"10","key":"1256_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","volume":"5","author":"LA Villani","year":"2016","unstructured":"L.A. Villani, B.K. Smith, K. Marcinko, R.J. Ford, L.A. Broadfield, A.E. Green, V.P. Houde, P. Muti, T. Tsakiridis, G.R. Steinberg, The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol. Metab. 5(10), 1048\u20131056 (2016). https:\/\/doi.org\/10.1016\/j.molmet.2016.08.014","journal-title":"Mol. Metab."},{"issue":"1","key":"1256_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s11658-024-00599-1","volume":"29","author":"C Anastasio","year":"2024","unstructured":"C. Anastasio, I. Donisi, V. Del Vecchio, A. Colloca, L. Mele, C. Sardu, R. Marfella, M.L. Balestrieri, N. D\u2019Onofrio, SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells. Cell. Mol. Biol. Lett. 29(1), 80 (2024). https:\/\/doi.org\/10.1186\/s11658-024-00599-1","journal-title":"Cell. Mol. Biol. Lett."},{"key":"1256_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.freeradbiomed.2023.09.006","volume":"208","author":"Y Zeng","year":"2023","unstructured":"Y. Zeng, H. Jiang, X. Zhang, J. Xu, X. Wu, Q. Xu, W. Cai, H. Ying, R. Zhou, Y. Ding, K. Ying, X. Song, Z. Chen, L. Zeng, L. Zhao, F. Yu, Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation. Free Radic Biol. Med. 208, 571\u2013586 (2023). https:\/\/doi.org\/10.1016\/j.freeradbiomed.2023.09.006","journal-title":"Free Radic Biol. Med."},{"key":"1256_CR19","doi-asserted-by":"publisher","first-page":"116140","DOI":"10.1016\/j.bcp.2024.116140","volume":"223","author":"H Huang","year":"2024","unstructured":"H. Huang, F.-L. Kung, Y.-W. Huang, C.-C. Hsu, J.-H. Guh, L.-C. Hsu, Sensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin. Biochem. Pharmacol. 223, 116140 (2024). https:\/\/doi.org\/10.1016\/j.bcp.2024.116140","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"1256_CR20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","volume":"6","author":"A Ali","year":"2023","unstructured":"A. Ali, B. Mekhaeil, O.-D. Biziotis, E.E. Tsakiridis, E. Ahmadi, J. Wu, S. Wang, K. Singh, G. Menjolian, T. Farrell, A. Mesci, S. Liu, T. Berg, J.L. Bramson, G.R. Steinberg, T. Tsakiridis, The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun. Biol. 6(1), 919 (2023). https:\/\/doi.org\/10.1038\/s42003-023-05289-w","journal-title":"Commun. Biol."},{"issue":"8","key":"1256_CR21","doi-asserted-by":"publisher","first-page":"101688","DOI":"10.1016\/j.xcrm.2024.101688","volume":"5","author":"J Zheng","year":"2024","unstructured":"J. Zheng, J. Lu, J. Qi, Q. Yang, H. Zhao, H. Liu, Z. Chen, L. Huang, Y. Ye, M. Xu, Y. Xu, T. Wang, M. Li, Z. Zhao, R. Zheng, S. Wang, H. Lin, C. Hu, C.S. Ling Chui, S.L. Au Yeung, S. Luo, O. Dimopoulou, P. Dixon, S. Harrison, Y. Liu, J. Robinson, J. Yarmolinsky, P. Haycock, J. Yuan, S. Lewis, Z. Yuan, T.R. Gaunt, G.D. Smith, G. Ning, R.M. Martin, B. Cui, W. Wang, Y. Bi, The effect of SGLT2 inhibition on prostate cancer: Mendelian randomization and observational analysis using electronic healthcare and cohort data. Cell. Rep. Med. 5(8), 101688 (2024). https:\/\/doi.org\/10.1016\/j.xcrm.2024.101688","journal-title":"Cell. Rep. Med."},{"issue":"1","key":"1256_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12885-021-09060-4","volume":"22","author":"J Du","year":"2022","unstructured":"J. Du, J. Gu, J. Deng, L. Kong, Y. Guo, C. Jin, Y. Bao, D. Fu, J. Li, The expression and survival significance of sodium glucose transporters in pancreatic cancer. BMC Cancer. 22(1), 116 (2022). https:\/\/doi.org\/10.1186\/s12885-021-09060-4","journal-title":"BMC Cancer"},{"key":"1256_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.canlet.2021.07.035","volume":"519","author":"D Ren","year":"2021","unstructured":"D. Ren, Y. Sun, D. Zhang, D. Li, Z. Liu, X. Jin, H. Wu, SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis. Cancer Lett. 519, 277\u2013288 (2021). https:\/\/doi.org\/10.1016\/j.canlet.2021.07.035","journal-title":"Cancer Lett."},{"issue":"3","key":"1256_CR24","first-page":"305","volume":"11","author":"K Tobita","year":"2003","unstructured":"K. Tobita, H. Kijima, S. Dowaki, H. Kashiwagi, Y. Ohtani, Y. Oida, H. Yamazaki, M. Nakamura, Y. Ueyama, M. Tanaka, S. Inokuchi, H. Makuuchi, Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int. J. Mol. Med. 11(3), 305\u2013309 (2003)","journal-title":"Int. J. Mol. Med."},{"key":"1256_CR25","doi-asserted-by":"publisher","unstructured":"G. Mucciolo, J. Araos Henr\u00edquez, M. Jihad, S. Pinto Teles, J.S. Manansala, W. Li, S. Ashworth, E.G. Lloyd, P.S.W. Cheng, W. Luo, A. Anand, A. Sawle, A. Piskorz, G. Biffi, EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Cancer Cell. 42(1) (2024). https:\/\/doi.org\/10.1016\/j.ccell.2023.12.002","DOI":"10.1016\/j.ccell.2023.12.002"},{"key":"1256_CR26","doi-asserted-by":"publisher","unstructured":"P. Wee, Z. Wang, Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel). 9(5) (2017). https:\/\/doi.org\/10.3390\/cancers9050052","DOI":"10.3390\/cancers9050052"},{"issue":"3","key":"1256_CR27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3892\/ijo.2016.3320","volume":"48","author":"N Ioannou","year":"2016","unstructured":"N. Ioannou, A.M. Seddon, A. Dalgleish, D. Mackintosh, F. Solca, H. Modjtahedi, Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. Int. J. Oncol. 48(3), 908\u2013918 (2016). https:\/\/doi.org\/10.3892\/ijo.2016.3320","journal-title":"Int. J. Oncol."},{"key":"1256_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40170-020-00226-5","volume":"8","author":"N Sharma","year":"2020","unstructured":"N. Sharma, A. Bhushan, J. He, G. Kaushal, V. Bhardwaj, Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase. Cancer Metab. 8, 19 (2020). https:\/\/doi.org\/10.1186\/s40170-020-00226-5","journal-title":"Cancer Metab."},{"key":"1256_CR29","doi-asserted-by":"publisher","unstructured":"X. Shi, M. Wang, Y. Zhang, X. Guo, M. Liu, Z. Zhou, Y. Zhao, R. He, Y. Gao, Y. Liu, S. Pan, M. Zhou, C. Zhao, T. Yin, X. Li, H. Wang, J. Yang, F. Zhu, M. Li, R. Qin, Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. EBioMedicine. 86, 104352. (2022). https:\/\/doi.org\/10.1016\/j.ebiom.2022.104352","DOI":"10.1016\/j.ebiom.2022.104352"},{"issue":"5","key":"1256_CR30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/0008-5472.CAN-15-2478","volume":"76","author":"S-O Lim","year":"2016","unstructured":"S.-O. Lim, C.-W. Li, W. Xia, H.-H. Lee, S.-S. Chang, J. Shen, J.L. Hsu, D. Raftery, D. Djukovic, H. Gu, W.-C. Chang, H.-L. Wang, M.-L. Chen, L. Huo, C.-H. Chen, Y. Wu, A. Sahin, S.M. Hanash, G.N. Hortobagyi, Hung, EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res. 76(5), 1284\u20131296 (2016). https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2478","journal-title":"Cancer Res."},{"issue":"30","key":"1256_CR31","doi-asserted-by":"publisher","first-page":"20813","DOI":"10.1074\/jbc.M114.575464","volume":"289","author":"H Makinoshima","year":"2014","unstructured":"H. Makinoshima, M. Takita, S. Matsumoto, A. Yagishita, S. Owada, H. Esumi, K. Tsuchihara, Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. J. Biol. Chem. 289(30), 20813\u201320823 (2014)","journal-title":"J. Biol. Chem."},{"issue":"W1","key":"1256_CR32","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Z. Tang, B. Kang, C. Li, T. Chen, Z. Zhang, GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47(W1), W556\u2013W560 (2019). https:\/\/doi.org\/10.1093\/nar\/gkz430","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"1256_CR33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41467-023-36296-4","volume":"14","author":"G Werba","year":"2023","unstructured":"G. Werba, D. Weissinger, E.A. Kawaler, E. Zhao, D. Kalfakakou, S. Dhara, L. Wang, H.B. Lim, G. Oh, X. Jing, N. Beri, L. Khanna, T. Gonda, P. Oberstein, C. Hajdu, C. Loomis, A. Heguy, M.H. Sherman, A.W. Lund, T.H. Welling, I. Dolgalev, A. Tsirigos, D.M. Simeone, Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Nat. Commun. 14(1), 797 (2023). https:\/\/doi.org\/10.1038\/s41467-023-36296-4","journal-title":"Nat. Commun."},{"issue":"1","key":"1256_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3892\/ijo.2018.4599","volume":"54","author":"X Zhang","year":"2019","unstructured":"X. Zhang, X. Zhang, X. Liu, P. Qi, H. Wang, Z. Ma, Y. Chai, MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer. Int. J. Oncol. 54(1), 199\u2013208 (2019). https:\/\/doi.org\/10.3892\/ijo.2018.4599","journal-title":"Int. J. Oncol."},{"key":"1256_CR35","doi-asserted-by":"publisher","first-page":"177002","DOI":"10.1016\/j.ejphar.2024.177002","volume":"983","author":"K Ren","year":"2024","unstructured":"K. Ren, X. Wang, R. Ma, H. Chen, T. Min, Y. Ma, X. Xie, W. Wang, X. Deng, Z. Zhou, K. Li, K. Zhu, N. Hao, C. Dang, T. Sun, H. Zhang, Dapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination. Eur. J. Pharmacol. 983, 177002 (2024). https:\/\/doi.org\/10.1016\/j.ejphar.2024.177002","journal-title":"Eur. J. Pharmacol."},{"key":"1256_CR36","doi-asserted-by":"publisher","first-page":"110821","DOI":"10.1016\/j.biopha.2020.110821","volume":"132","author":"J Zhou","year":"2020","unstructured":"J. Zhou, J. Zhu, S.-J. Yu, H.-L. Ma, J. Chen, X.-F. Ding, G. Chen, Y. Liang, Q. Zhang, Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway. Biomed. Pharmacother. 132, 110821 (2020). https:\/\/doi.org\/10.1016\/j.biopha.2020.110821","journal-title":"Biomed. Pharmacother"},{"issue":"2","key":"1256_CR37","doi-asserted-by":"publisher","first-page":"101605","DOI":"10.1016\/j.diabet.2025.101605","volume":"51","author":"YK Cho","year":"2025","unstructured":"Y.K. Cho, S. Kim, M.J. Kim, W.J. Lee, Y.-J. Kim, C.H. Jung, New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident pancreatic cancer: A nationwide population-based cohort study. Diabetes Metab. 51(2), 101605 (2025). https:\/\/doi.org\/10.1016\/j.diabet.2025.101605","journal-title":"Diabetes Metab."},{"issue":"11","key":"1256_CR38","doi-asserted-by":"publisher","first-page":"492","DOI":"10.5414\/CP204465","volume":"61","author":"Y Tanaka","year":"2023","unstructured":"Y. Tanaka, S. Yokoyama, C. Nakagawa, T. Uno, K. Hosomi, Association between sodium-glucose cotransporter 2 inhibitors and pancreatic cancer in the Japanese working-age population. Int. J. Clin. Pharmacol. Ther. 61(11), 492\u2013502 (2023). https:\/\/doi.org\/10.5414\/CP204465","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"2","key":"1256_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"J. Kim, M. Kundu, B. Viollet, K.-L. Guan, AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell. Biol. 13(2), 132\u2013141 (2011). https:\/\/doi.org\/10.1038\/ncb2152","journal-title":"Nat. Cell. Biol."},{"issue":"5","key":"1256_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41568-021-00344-2","volume":"21","author":"H Xia","year":"2021","unstructured":"H. Xia, D.R. Green, W. Zou, Autophagy in tumour immunity and therapy. Nat. Rev. Cancer. 21(5), 281\u2013297 (2021). https:\/\/doi.org\/10.1038\/s41568-021-00344-2","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"1256_CR41","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrd3802","volume":"11","author":"DC Rubinsztein","year":"2012","unstructured":"D.C. Rubinsztein, P. Codogno, B. Levine, Autophagy modulation as a potential therapeutic target for diverse diseases. Nat. Rev. Drug Discov. 11(9), 709\u2013730 (2012). https:\/\/doi.org\/10.1038\/nrd3802","journal-title":"Nat. Rev. Drug Discov"},{"key":"1256_CR42","doi-asserted-by":"publisher","first-page":"101679","DOI":"10.1016\/j.redox.2020.101679","volume":"36","author":"W Ornatowski","year":"2020","unstructured":"W. Ornatowski, Q. Lu, M. Yegambaram, A.E. Garcia, E.A. Zemskov, E. Maltepe, J.R. Fineman, T. Wang, S.M. Black, Complex interplay between autophagy and oxidative stress in the development of pulmonary disease. Redox Biol. 36, 101679 (2020). https:\/\/doi.org\/10.1016\/j.redox.2020.101679","journal-title":"Redox Biol."},{"issue":"6","key":"1256_CR43","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00204-023-03476-6","volume":"97","author":"B Wang","year":"2023","unstructured":"B. Wang, Y. Wang, J. Zhang, C. Hu, J. Jiang, Y. Li, Z. Peng, ROS-induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosis. Arch. Toxicol. 97(6), 1439\u20131451 (2023). https:\/\/doi.org\/10.1007\/s00204-023-03476-6","journal-title":"Arch. Toxicol."},{"issue":"1","key":"1256_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41420-021-00801-9","volume":"8","author":"CH Park","year":"2022","unstructured":"C.H. Park, B. Lee, M. Han, W.J. Rhee, M.S. Kwak, T.-H. Yoo, J.-S. Shin, Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells. Cell. Death Discov. 8(1), 12 (2022). https:\/\/doi.org\/10.1038\/s41420-021-00801-9","journal-title":"Cell. Death Discov"},{"key":"1256_CR45","doi-asserted-by":"publisher","first-page":"117183","DOI":"10.1016\/j.taap.2024.117183","volume":"495","author":"J Luo","year":"2025","unstructured":"J. Luo, M. He, C. Liang, X. Huang, Y. Zhu, D. Hu, J. Yan, M. Li, H. Lin, W. Liao, J. Bin, Z. Guan, C. Zheng, Y. Liao, Canagliflozin reverses doxorubicin-induced cardiotoxicity via restoration of autophagic homeostasis. Toxicol. Appl. Pharmacol. 495, 117183 (2025). https:\/\/doi.org\/10.1016\/j.taap.2024.117183","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"30","key":"1256_CR46","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1200\/JCO.22.02770","volume":"41","author":"MJ Moore","year":"2023","unstructured":"M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, S. Gallinger, H.J. Au, P. Murawa, D. Walde, R.A. Wolff, D. Campos, R. Lim, K. Ding, G. Clark, T. Voskoglou-Nomikos, M. Ptasynski, W. Parulekar, Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 41(30), 4714\u20134720 (2023). https:\/\/doi.org\/10.1200\/JCO.22.02770","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"1256_CR47","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1200\/JCO.22.02630","volume":"41","author":"S Qin","year":"2023","unstructured":"S. Qin, J. Li, Y. Bai, Z. Wang, Z. Chen, R. Xu, J. Xu, H. Zhang, J. Chen, Y. Yuan, T. Liu, L. Yang, H. Zhong, D. Chen, L. Shen, C. Hao, D. Fu, Y. Cheng, J. Yang, Q. Wang, B. Qin, H. Pan, J. Zhang, X. Bai, Q. Zheng, Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. J. Clin. Oncol. 41(33), 5163\u20135173 (2023). https:\/\/doi.org\/10.1200\/JCO.22.02630","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"1256_CR48","doi-asserted-by":"publisher","first-page":"119359","DOI":"10.1016\/j.bbamcr.2022.119359","volume":"1869","author":"LA Orofiamma","year":"2022","unstructured":"L.A. Orofiamma, D. Vural, C.N. Antonescu, Control of cell metabolism by the epidermal growth factor receptor. Biochim. Biophys. Acta Mol. Cell. Res. 1869(12), 119359 (2022). https:\/\/doi.org\/10.1016\/j.bbamcr.2022.119359","journal-title":"Biochim. Biophys. Acta Mol. Cell. Res."},{"issue":"18","key":"1256_CR49","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.7150\/jca.21035","volume":"8","author":"M Ye","year":"2017","unstructured":"M. Ye, S. Wang, T. Wan, R. Jiang, Y. Qiu, L. Pei, N. Pang, Y. Huang, Y. Huang, Z. Zhang, L. Yang, Combined Inhibitions of Glycolysis and AKT\/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer. J. Cancer. 8(18), 3774\u20133784 (2017). https:\/\/doi.org\/10.7150\/jca.21035","journal-title":"J. Cancer"},{"issue":"10","key":"1256_CR50","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1158\/1535-7163.MCT-12-1188","volume":"12","author":"SM Kim","year":"2013","unstructured":"S.M. Kim, M.R. Yun, Y.K. Hong, F. Solca, J.-H. Kim, H.-J. Kim, B.C. Cho, Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol. Cancer Ther. 12(10), 2145\u20132156 (2013). https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1188","journal-title":"Mol. Cancer Ther."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01256-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01256-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01256-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:35:51Z","timestamp":1790642151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01256-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1256"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01256-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8820380\/v1","asserted-by":"object"}]},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Peking University First Hospital (approval no. 2024-194-002). Written informed consent was obtained from the patient. Animal experiments were approved by the Institutional Animal Care and Use Committee of Peking University First Hospital (approval no. J2025049) and conducted in accordance with institutional guidelines for animal welfare.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"125"}}